THOUSAND OAKS, Calif. The U.S. Federal District Court in Boston has granted a motion in favor of Amgen in a judgment the company had filed stating the Roche has infringed on its EPO patent number 5,955,422.
The case is in reference to Roche’s new pegylated-erthropoietin product for anemia. The drug is designed to stimulate the pre-cursors of red blood cells, which would solve the problem of anemia, both natural and due to chemotherapy.
The case will go to trial on Sept. 4, where Amgen will argue its claim of infringement for additional patents and where Roche will argue the validity and enforceability of Amgen’s patents.